BACKGROUND: Human caliciviruses (Norovirus and Sapovirus) are important acute gastroenteritis agents. The Norovirus (NoV) disease is usually self-limited; however, prolonged viral excretion and complications have been reported, mainly in immunosuppressed individuals. OBJECTIVES: In this prospective study, we have monitored allogeneic stem cell transplant (ASCT) patients for human calicivirus infection. STUDY DESIGN: Ten ASCT patients were monitored for NoV and sapoviruses (SaV) infection, for a period of five months to a maximum of one year. Prolonged NoV excretion and long term viral RNA in the blood were assessed by multiplex RT-PCR targeting region C of the viral capsid. Secretor status of the patients was determined by enzyme immunoassay using Ulex Europaeus agglutinin. Partial genomic sequencing and phylogenetic analysis were performed to characterize the viral genotypes. RESULTS: NoV was detected in six out of ten patients (60%). Prolonged viral excretion in feces (mean of 61.6 days) and long term presence of NoV RNA in the sera (mean of 33.6 days) of the patients were observed. SaV was not detected in any of the samples. All patients had diarrhea, vomiting and fever during NoV positivity. All NoV-positive samples were characterized as GI.3 NoV. Three Nov-infected patients presented with acute intestinal graft versus host disease. CONCLUSIONS: This study brings important information on NoV course of infection in ASCT patients. It also provides evidence for long term viral RNA in the blood highlighting the importance of the inclusion of NoV screening in the routine testing performed before transplantation and during follow-up of these patients.
BACKGROUND: Human caliciviruses (Norovirus and Sapovirus) are important acute gastroenteritis agents. The Norovirus (NoV) disease is usually self-limited; however, prolonged viral excretion and complications have been reported, mainly in immunosuppressed individuals. OBJECTIVES: In this prospective study, we have monitored allogeneic stem cell transplant (ASCT) patients for human calicivirusinfection. STUDY DESIGN: Ten ASCT patients were monitored for NoV and sapoviruses (SaV) infection, for a period of five months to a maximum of one year. Prolonged NoV excretion and long term viral RNA in the blood were assessed by multiplex RT-PCR targeting region C of the viral capsid. Secretor status of the patients was determined by enzyme immunoassay using Ulex Europaeus agglutinin. Partial genomic sequencing and phylogenetic analysis were performed to characterize the viral genotypes. RESULTS: NoV was detected in six out of ten patients (60%). Prolonged viral excretion in feces (mean of 61.6 days) and long term presence of NoV RNA in the sera (mean of 33.6 days) of the patients were observed. SaV was not detected in any of the samples. All patients had diarrhea, vomiting and fever during NoV positivity. All NoV-positive samples were characterized as GI.3 NoV. Three Nov-infectedpatients presented with acute intestinal graft versus host disease. CONCLUSIONS: This study brings important information on NoV course of infection in ASCT patients. It also provides evidence for long term viral RNA in the blood highlighting the importance of the inclusion of NoV screening in the routine testing performed before transplantation and during follow-up of these patients.
Authors: Jacob A Van Winkle; Bridget A Robinson; A Mack Peters; Lena Li; Ruth V Nouboussi; Matthias Mack; Timothy J Nice Journal: Cell Host Microbe Date: 2018-11-01 Impact factor: 21.023
Authors: Wen Dang; Yuebang Yin; Yijin Wang; Wenshi Wang; Junhong Su; Dave Sprengers; Luc J W van der Laan; Krzysztof Felczak; Krzysztof W Pankiewicz; Kyeong-Ok Chang; Marion P G Koopmans; Herold J Metselaar; Maikel P Peppelenbosch; Qiuwei Pan Journal: Antimicrob Agents Chemother Date: 2017-10-24 Impact factor: 5.191
Authors: M Schmidt-Hieber; J Bierwirth; D Buchheidt; O A Cornely; M Hentrich; G Maschmeyer; E Schalk; J J Vehreschild; Maria J G T Vehreschild Journal: Ann Hematol Date: 2017-11-24 Impact factor: 3.673
Authors: Harini D de Silva; Rosemary A Ffrench; Maya Korem; Eva Orlowski; David J Curtis; Andrew Spencer; Sharon Avery; Sushrut Patil; Catherine Orla Morrissey Journal: Clin Transl Immunology Date: 2018-10-05
Authors: Tulio Machado Fumian; Juliana da Silva Ribeiro de Andrade; José Paulo Gagliardi Leite; Marize Pereira Miagostovich Journal: PLoS One Date: 2016-04-26 Impact factor: 3.240
Authors: Divya Samantha Kondapi; Sasirekha Ramani; Mary K Estes; Robert L Atmar; Pablo C Okhuysen Journal: Open Forum Infect Dis Date: 2021-03-14 Impact factor: 3.835